Alerus Financial NA reduced its stake in iShares Biotechnology ETF (NASDAQ:IBB – Get Rating) by 26.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,913 shares of the financial services provider’s stock after selling 1,372 shares during the quarter. Alerus Financial NA’s holdings in iShares Biotechnology ETF were worth $597,000 at the end of the most recent quarter.
A number of other hedge funds have also recently bought and sold shares of the business. Consolidated Planning Corp purchased a new stake in shares of iShares Biotechnology ETF in the third quarter worth approximately $32,000. Future Financial Wealth Managment LLC acquired a new position in shares of iShares Biotechnology ETF in the 4th quarter valued at approximately $30,000. Gradient Investments LLC increased its position in shares of iShares Biotechnology ETF by 99.0% during the fourth quarter. Gradient Investments LLC now owns 201 shares of the financial services provider’s stock worth $31,000 after acquiring an additional 100 shares in the last quarter. Steward Financial Group LLC acquired a new stake in shares of iShares Biotechnology ETF during the 4th quarter worth about $34,000. Finally, Dixon Hughes Goodman Wealth Advisors LLC bought a new stake in shares of iShares Biotechnology ETF during the 4th quarter valued at $38,000. 63.88% of the stock is owned by hedge funds and other institutional investors.
Shares of IBB stock traded down $1.06 on Wednesday, hitting $113.52. 89,021 shares of the stock were exchanged, compared to its average volume of 2,871,672. iShares Biotechnology ETF has a one year low of $105.39 and a one year high of $177.37. The firm’s 50 day moving average is $123.77 and its two-hundred day moving average is $134.31.
About iShares Biotechnology ETF (Get Rating)
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
See Also
- Get a free copy of the StockNews.com research report on iShares Biotechnology ETF (IBB)
- Institutions Ring The Register On Toll Brothers Stock
- Agilent Technologies Is Bottoming But Don’t Buy It Yet
- Dick’s Sporting Goods Falls Flat On Weak Guidance
- Investors Can Get 5%-Plus Dividend Yields on These 3 Buys
- It’s Time to Buy into Planet Fitness Stock
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Get Rating).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.